Bullboard Post History

by freemason657


Delisted

This stock is absolutely WORTHLESS

0 stars

It has nowhere to go expect down!

May 3, 2002

T.QLT

QLT Phase III occult AMD trial not required

0 stars

With Medicare's recent decision to reimburse the costs of Visudyne in the...

October 22, 2001

T.QLT

QLT is an attractive Biotech Investment

0 stars

These are just some of the reasons for this: 1. Visudyne is a BLOCKBUSTER...

June 11, 2001

T.QLT

Now who here is an expert in proteomics?

0 stars

Kinetek Pharmaceuticals' functional proteomics platform bridges the gap...

June 8, 2001

T.QLT

Deutsche Bank AB reiterates BUY on QLT

0 stars

QLT Inc. Reiterated `Buy' at Deutsche Banc AB By Sybil Carlson Princeton,...

June 8, 2001

T.QLT

RE: News

0 stars

As the PR indicated the transaction consists of an initial equity investment...

June 8, 2001

T.QLT

QLT Expands Product Pipeline with agreement

0 stars

QLT enters into research and license agreement with Kinetek Deal moves...

June 7, 2001

T.QLT

Visudyne sales expected to increase ramp-up

0 stars

Earnings from Visudyne sales are ramping up. As of January 01, 2001...

June 1, 2001

T.QLT

Deutsche Bank AB multiple on QLT

0 stars

At US$22 QLT is trading at approximately 30x their tax-adjusted 2002 EPS...

May 28, 2001

T.QLT

RE: Deutsche Bank AB recommends BUY on QLT

0 stars

In a report Deutsche Bank presented comments on the the upcoming FDA approval...

May 28, 2001

T.QLT

RE: QLT leads the way

0 stars

Sometimes it is necessary to "Read between the lines" and sometimes it is not...

May 22, 2001

T.QLT

RE: QLT leads the way

0 stars

This is taken from the work being undertaken by the Alberta Heritage...

May 21, 2001

T.QLT

RE: QLT leads the way

0 stars

cancer vaccine QLT is also investigating the use of a photosensitizer in...

May 21, 2001

T.QLT

RE: Here are some facts on Visudyne

0 stars

Repost: 1. Data presented at a symposium held during the annual...

May 18, 2001

T.QLT

RE: NB increases Visudyne 2001 sales estimates

0 stars

" [We] are raising our 2001 sales estimates from US$243 to US$251.5 million...

May 17, 2001

T.QLT

RE: NB increases Visudyne 2001 sales estimates

0 stars

The "average" PE for biotechnolgy stocks, with expected growth rates...

May 16, 2001

T.QLT

RE: Here are some facts on Visudyne

0 stars

In the extension trial, the average visual acuity of patients originally...

May 15, 2001

T.QLT

Here are some facts on Visudyne

0 stars

1. Data presented at a symposium held during the annual Association for...

May 15, 2001

T.QLT

NB increases Visudyne 2001 sales estimates

0 stars

EVENT: A second Phase III trial for Visudyne will be required to obtain U.S...

May 11, 2001

T.QLT

RE: Visudyne shows benefit in Occult AMD patients

0 stars

``Based on these results, ocular photodynamic therapy with Visudyne should be...

May 10, 2001